Granisetron Hydrochloride for Injection

This product is a highly selective 5-HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Factors such as radiotherapy, chemotherapy and surgery can cause enterochromaffin cells to release 5-HT, which can activate the 5-HT3 receptors of the central nervous system or vagus nerve and cause vomiting reflex. The mechanism of this product to control nausea and vomiting is to antagonize the 5-HT3 receptors in the central chemoreceptor area and the peripheral vagus nerve endings, thereby inhibiting the occurrence of nausea and vomiting. This product has high selectivity and no adverse reactions such as extrapyramidal reactions and excessive sedation.

Granisetron Hydrochloride

This product is white loose mass or powder.

Used for nausea and vomiting caused by radiotherapy and cytotoxic chemotherapy.

Intravenous injection. Adults: usually 3 mg, diluted with 20-50 ml of 5% glucose injection or 0.9% sodium chloride injection, intravenously injected 30 minutes before chemotherapy, and the administration time should exceed 5 minutes. Intravenous drip. Add to 5% glucose injection or 0.9% sodium chloride injection and drip intravenously. Intravenous drip 30 minutes before chemotherapy, and the administration time should be no less than 60 minutes. Most patients only need to take the drug once, and the prevention effect on nausea and vomiting can exceed 24 hours. If necessary, the drug can be increased by 1-2 times, but the maximum daily dose should not exceed 9 mg. No dosage adjustment is required for patients with liver and kidney dysfunction.

Common adverse reactions include headache, fatigue, fever, constipation, and occasional transient asymptomatic increase in liver aminotransferase. These reactions are mild and do not require special treatment.

1. Patients who are allergic to this product or related compounds are prohibited from using this product. 2. Patients with gastrointestinal obstruction are prohibited from using this product.

1 Granisetron is metabolized by the hepatic cytochrome P450 drug metabolizing enzyme. Inducing or inhibiting this enzyme can change the clearance rate and half-life of granisetron. 2 Granisetron itself does not induce or inhibit the cytochrome P450 drug metabolizing enzyme system and can be used in combination with benzodiazepines, neuroleptics and anti-ulcer drugs.

Keep away from light and sealed. Valid for 12 months.

3mg

China National Medicines Guorui Pharmaceutical Co., Ltd.

• Founded in:

  1998-08-05

• Address:

  No. 16, Chaoyang East Road, Economic and Technological Development Zone, Huainan City, Anhui Province

• Tax NO.:

  9134040072334670XN

• Registered Funds:

  483.0167 million yuan

• Email:

  Log in to view